EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia

Joel Simrén, Andrea L Benedet, Guglielmo Di Molfetta, Ilaria Pola, Kübra Tan, Valentina Cantoni, Ilenia Libri, Jasmine Rivolta, Roberta Ghidoni iD, Henrik Zetterberg, Barbara Borroni, Nicholas J Ashton

European Journal of Neurology · 2026-07 · 33 (7)

DOI: 10.1111/ene.70704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 12.07.2026. Verfasst von Joel Simrén und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothe…. Hauptthemen laut MEDLINE: C9orf72 Protein, Progranulins, Frontotemporal Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bluefield Project, Beiglers stiftelse, Stiftelsen för Gamla Tjänarinnor.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers reflecting the complex pathophysiology of genetic frontotemporal dementia (FTD) will be increasingly important with the advent of therapeutic trials aiming to slow or prevent the disease. In this study, we aimed to identify blood biomarker candidates using a multiplex panel of CNS‐related proteins.

Methods

We cross‐sectionally evaluated 67 carriers (21 presymptomatic and 46 symptomatic) of pathogenic FTD‐causing mutations in the GRN ( n = 30 symptomatic) and C9orf72 ( n = 16 symptomatic) genes and 42 matched non‐carriers. Clinical severity was estimated using the CDR Dementia Staging Instrument with National Alzheimer Coordinating Centre Frontotemporal Lobar Degeneration component (CDR plus NACC FTLD). A total of 124 CNS‐related proteins were measured in plasma using the NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) CNS panel. Group‐level changes were then investigated using linear and non‐linear regression models.

Results

In GRN‐ and C9orf72 ‐FTD, neurofilament light (NfL) was the most clearly altered protein compared with non‐carriers ( GRN: β [95% CI] = 4.0 standard deviations [3.6–4.4], C9orf72 : β = 2.8 [2.2–3.4]), followed by neurofilament heavy (NfH; GRN : β = 0.83 [0.39–1.3], C9orf72 : β = 1.4 [0.8–2.0]). Proteins exclusively altered in GRN ‐FTD included glial fibrillary acidic protein (GFAp; β = 0.50 [0.20–0.81]) and vascular cell adhesion protein 1 (VCAM1; Standardized β = −0.90 [−1.4 to −0.38]), changing with increasing disease severity. Neuronal pentraxin receptor (NPTXR; β = −0.94 [−1.5 to −0.4]) was selectively reduced in C9orf72‐ FTD. Nominally changed proteins in C9orf72 ‐FTD included several inflammatory mediators.

Conclusions

Using this multiplex panel, established markers recapitulated previously established trends, while less‐studied biomarker candidates were also identified. If validated in independent cohorts, these candidates could broaden the repertoire of blood biomarkers reflecting genetic FTD pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C9orf72 ProteinProgranulinsFrontotemporal DementiaHumansFemaleBiomarkersMaleProteomicsMiddle AgedCross-Sectional StudiesAgedNeurofilament Proteins

Stichwörter der Autor:innen

biomarkersfrontotemporal dementiaproteomics

Substanzen

C9orf72 ProteinProgranulinsC9orf72 protein, humanGRN protein, humanBiomarkersneurofilament protein LNeurofilament Proteins

Autor:innen und Institutionen

  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Department of Neurodegenerative Disease, Institute of Neurology, UCL, London, UK.
  • UK Dementia Research Institute, UCL, London, UK.

ORCID-Profile: Roberta Ghidoni

Förderung

  • Bluefield Project
  • Beiglers stiftelse
  • Stiftelsen för Gamla Tjänarinnor

Zitieren

APA

Simrén, J., Benedet, A. L., Di Molfetta, G., Pola, I., Tan, K., Cantoni, V., Libri, I., Rivolta, J., Ghidoni, R., Zetterberg, H., Borroni, B., & Ashton, N. J. (2026). Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia. European Journal of Neurology, 33(7). https://doi.org/10.1111/ene.70704

Vancouver

Simrén J, Benedet AL, Di Molfetta G, Pola I, Tan K, Cantoni V, et al. Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia. European Journal of Neurology. 2026;33(7). doi:10.1111/ene.70704

BibTeX
@article{Simrn2026,
  author = {Simrén, Joel and Benedet, Andrea L and Di Molfetta, Guglielmo and Pola, Ilaria and Tan, Kübra and Cantoni, Valentina and Libri, Ilenia and Rivolta, Jasmine and Ghidoni, Roberta and Zetterberg, Henrik and Borroni, Barbara and Ashton, Nicholas J},
  title = {Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {7},
  doi = {10.1111/ene.70704}
}
Kostenlos starten →